Menu
Currency
GWAS Study

Trans-Ancestral Genetic Risk Factors for Treatment-Related Type 2 Diabetes Mellitus in Survivors of Childhood Cancer.

Im C, Neupane A, Baedke JL et al.

38652878 PubMed ID
GWAS Study Type
9067 Participants
78 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

IC
Im C
NA
Neupane A
BJ
Baedke JL
LB
Lenny B
DA
Delaney A
DS
Dixon SB
CE
Chow EJ
MS
Mostoufi-Moab S
YT
Yang T
RM
Richard MA
GM
Gramatges MM
LP
Lupo PJ
SN
Sharafeldin N
BS
Bhatia S
AG
Armstrong GT
HM
Hudson MM
NK
Ness KK
RL
Robison LL
YY
Yasui Y
WC
Wilson CL
SY
Sapkota Y
Chapter II

Abstract

Summary of the research findings

Purpose: Type 2 diabetes mellitus (T2D) is a prevalent long-term complication of treatment in survivors of childhood cancer, with marked racial/ethnic differences in burden. In this study, we investigated trans-ancestral genetic risks for treatment-related T2D.

261 European ancestry cases, 2,841 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

9067
Total Participants
GWAS
Study Type
Yes
Replicated
270 European ancestry cases, 5,695 European ancestry controls
Replication Participants
European, African American or Afro-Caribbean
Ancestry
U.S., Canada
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.